Additionally, liraglutide and DA5-CH attenuate tau hyperphosphorylation in the hippocampus from AD mice [24, 25, 33] and non-human primates [34], and exenatide and other GLP1 agonists increase cortical and hippocampal synaptic density in both genetic and Aß-induced AD models [11, 19–22, 33, 35, 36]. This evidence concerns the gene MAPT and Alzheimer disease.